Wellframe Closes $8.5 Million Series A For Chronic Disease Apps

3-25-2013 11-26-33 PM

Wellframe announces the closing of an $8.5 million Series A round led by DJF, with additional capital provided by Formation 8, Waterline Ventures, and Queensbridge Venture Partners. The new round comes just five months after Wellframe closed a $1.5 million seed round solicited from a group of angel investors that included DFJ’s founder Tim Draper, as well as Athenahealth CEO Jonathan Bush, and British Medical Association president Sir Sabaratnam Arulkumaran. Wellframe is also a 2012 Rock Health graduate, and received early-stage seed funding as part of its participation in the accelerator. In total, the company has raised just north of $10 million since its formation.

Wellframe was launched in 2010 by a team of Harvard and MIT trained physicians and computer scientists. The team’s first product was a cardiac rehabilitation app that simplifies the rehabilitation process for newly discharged patients by presenting a daily checklist of tasks that the patient needs to complete in order to stay on track with their rehabilitation program. The checklists are generated by computer algorithms that track the patient’s progress through the cardiac rehabilitation process. Clinicians at the hospital are able to monitor each patient’s progress, and send personalized tasks and messages through a population health dashboard. The app is designed to help establish long-term behavioral changes and improve overall treatment adherence.

A clinical trial investigating the app’s efficacy was conducted at South Shore Hospital (MA) and recently published in The Journal of Cardiopulmonary Rehabilitation and Prevention. The study followed 26 patients who were enrolled in traditional cardiac rehabilitation and also enrolled in Wellframe’s cardiac rehabilitation app. After 30 days, utilization and outcomes were measured. Patient’s engaged with the rehab app on 90 percent of the days included in the study period, with 83 percent reporting a positive experience. Clinician’s were interviewed at the conclusion of the study, and reported that Wellframe’s platform improved communication, clinical insight, patient participation, program efficiency, and led to a reduction in office visit cancellations.

Since closing its seed round, Wellframe has expanded its clinical presence beyond cardiac rehabilitation, and now markets additional platforms that help hospitals improve outcomes within the mental health, diabetes, and transplant medicine populations. The company has ambitions to continue extending, validating, and improving its platforms to address wide variety of rehabilitation and chronic disease management needs.

Enjoy HIStalk Connect? Sign up for update alerts, or follow us at @HIStalkConnect.

↑ Back to top

Founding Sponsors

Platinum Sponsors